Literature DB >> 35547416

Treatment of Leptomeningeal Carcinomatosis Following Treatment of Cerebellar Metastasis of HER2+ (Human Epidermal Growth Factor Receptor 2 Positive) Breast Cancer: Case Report and Review of Literature.

Parker D Smith1, Lokeshwar S Bhenderu2, Sarayu Kommuri3, Erin E Fleener4, Jason M Hoover3.   

Abstract

Leptomeningeal carcinomatosis (LC) after metastasis of breast cancer is a rare occurrence with potentially devastating complications. Treatment options are limited, and there is a lack of literature on this topic. We report the case of a 38-year-old woman with estrogen/progesterone receptor negative (ER/PR-), human epidermal growth factor receptor 2 positive (HER2+) invasive ductal carcinoma of the left breast who underwent bilateral mastectomies with axillary lymph node dissection and chemotherapy treatment. The patient returned 11 months later with persistent headaches. Imaging and resection found cerebellar metastasis of the breast carcinoma. The brain metastasis was treated with further chemotherapy and stereotactic radiosurgery. Follow-up imaging showed the development of small lesions outside the radiation site. Metabolic studies were performed to determine if the new lesions were due to tumor recurrence or radiation necrosis, but the studies were inconclusive as to the etiology of these lesions. The patient later developed LC that was successfully treated with full resolution of the disease using intrathecal trastuzumab. There are currently no consensuses on treatment guidelines for treating LC. Here, we demonstrate successful treatment of LC from an ER/PR-, HER2+ breast carcinoma with intrathecal trastuzumab.
Copyright © 2022, Smith et al.

Entities:  

Keywords:  her2; intrathecal trastuzumab; leptomeningeal carcinomatosis; radiation necrosis; radiosurgery

Year:  2022        PMID: 35547416      PMCID: PMC9090228          DOI: 10.7759/cureus.24008

Source DB:  PubMed          Journal:  Cureus        ISSN: 2168-8184


  17 in total

Review 1.  Accuracy of 18F-FDOPA Positron Emission Tomography and 18F-FET Positron Emission Tomography for Differentiating Radiation Necrosis from Brain Tumor Recurrence.

Authors:  Jun Yu; Jingwei Zheng; Weilin Xu; Jiaqi Weng; Liansheng Gao; Li Tao; Feng Liang; Jianmin Zhang
Journal:  World Neurosurg       Date:  2018-04-04       Impact factor: 2.104

Review 2.  Leptomeningeal carcinomatosis in patients with breast cancer.

Authors:  Maria Alice Franzoi; Gabriel N Hortobagyi
Journal:  Crit Rev Oncol Hematol       Date:  2019-02-01       Impact factor: 6.312

3.  Lapatinib plus capecitabine for HER2-positive advanced breast cancer.

Authors:  Charles E Geyer; John Forster; Deborah Lindquist; Stephen Chan; C Gilles Romieu; Tadeusz Pienkowski; Agnieszka Jagiello-Gruszfeld; John Crown; Arlene Chan; Bella Kaufman; Dimosthenis Skarlos; Mario Campone; Neville Davidson; Mark Berger; Cristina Oliva; Stephen D Rubin; Steven Stein; David Cameron
Journal:  N Engl J Med       Date:  2006-12-28       Impact factor: 91.245

4.  Leptomeningeal metastasis after surgical resection of brain metastases.

Authors:  T C van der Ree; D W Dippel; C J Avezaat; P A Sillevis Smitt; C J Vecht; M J van den Bent
Journal:  J Neurol Neurosurg Psychiatry       Date:  1999-02       Impact factor: 10.154

5.  Intrathecal trastuzumab in the management of HER2+ breast leptomeningeal disease: a single institution experience.

Authors:  Nicholas B Figura; Wendy Long; Michael Yu; Timothy J Robinson; Sepideh Mokhtari; Arnold B Etame; Nam D Tran; Roberto Diaz; Hatem Soliman; Heather S Han; Solmaz Sahebjam; Peter A Forsyth; Kamran A Ahmed
Journal:  Breast Cancer Res Treat       Date:  2018-02-01       Impact factor: 4.872

Review 6.  Demographics of brain metastasis.

Authors:  J D Johnson; B Young
Journal:  Neurosurg Clin N Am       Date:  1996-07       Impact factor: 2.509

Review 7.  The biology of erbB-2/neu/HER-2 and its role in cancer.

Authors:  N E Hynes; D F Stern
Journal:  Biochim Biophys Acta       Date:  1994-12-30

8.  Utility of intravoxel incoherent motion MR imaging for distinguishing recurrent metastatic tumor from treatment effect following gamma knife radiosurgery: initial experience.

Authors:  D Y Kim; H S Kim; M J Goh; C G Choi; S J Kim
Journal:  AJNR Am J Neuroradiol       Date:  2014-06-26       Impact factor: 3.825

9.  Differentiating radiation necrosis from tumor progression in brain metastases treated with stereotactic radiotherapy: utility of intravoxel incoherent motion perfusion MRI and correlation with histopathology.

Authors:  Jay S Detsky; Julia Keith; John Conklin; Sean Symons; Sten Myrehaug; Arjun Sahgal; Chinthaka C Heyn; Hany Soliman
Journal:  J Neurooncol       Date:  2017-07-03       Impact factor: 4.130

10.  A Liquid Biopsy to Assess Brain Tumor Recurrence: Presence of Circulating Mo-MDSC and CD14+ VNN2+ Myeloid Cells as Biomarkers That Distinguish Brain Metastasis From Radiation Necrosis Following Stereotactic Radiosurgery.

Authors:  David C Soler; Amber Kerstetter-Fogle; Theresa Elder; Alankrita Raghavan; Jill S Barnholtz-Sloan; Kevin D Cooper; Thomas S McCormick; Andrew E Sloan
Journal:  Neurosurgery       Date:  2020-12-15       Impact factor: 4.654

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.